AD80 HAS HIGHER POTENCY COMPARED TO CLINICALLY USED FLT3 INHIBITORS IN FLT3-ITD AML CELLS
LBL Mirandaa, NO Rossinib, K Limac, DA Pereir-Martinsd, JJ Schuringad, EM Regoc, F Trainae, MVB Diasb, JA Machad-Netoa
a Department of Pharmacology, Institute of Biomedical Sciences, Universidade de São Paulo (USP), São Paulo, Brazil
b Department of Microbiology, Institute of Biomedical Sciences, Universidade de São Paulo (USP), São Paulo, Brazil
c Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Hematology Division, Faculdade de Medicina, Universidade de São Paulo (USP), São Paulo, Brazil
d Department of Experimental Hematology, Cancer Research Center Groningen, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
e Department of Medical Imaging, Haematology, and Oncology, Faculdade de Medicina de Ribeirão Preto (FMRP), Universidade de São Paulo (USP), Ribeirão Preto, Brazil
Read
245
Timeswas read the article
125
Total PDF
120
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 May | 25 | 18 | 43 |
| 2024 April | 30 | 19 | 49 |
| 2024 March | 21 | 12 | 33 |
| 2024 February | 12 | 21 | 33 |
| 2024 January | 4 | 2 | 6 |
| 2023 December | 9 | 20 | 29 |
| 2023 November | 10 | 26 | 36 |
| 2023 October | 9 | 7 | 16 |
